211 related articles for article (PubMed ID: 22265717)
1. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.
Martin CK; Dirksen WP; Shu ST; Werbeck JL; Thudi NK; Yamaguchi M; Wolfe TD; Heller KN; Rosol TJ
Oral Oncol; 2012 Jun; 48(6):491-9. PubMed ID: 22265717
[TBL] [Abstract][Full Text] [Related]
2. Bone-invasive oral squamous cell carcinoma in cats: pathology and expression of parathyroid hormone-related protein.
Martin CK; Tannehill-Gregg SH; Wolfe TD; Rosol TJ
Vet Pathol; 2011 Jan; 48(1):302-12. PubMed ID: 20940448
[TBL] [Abstract][Full Text] [Related]
3. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
4. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.
Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL
Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723
[TBL] [Abstract][Full Text] [Related]
5. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells.
Sambandam Y; Ethiraj P; Hathaway-Schrader JD; Novince CM; Panneerselvam E; Sundaram K; Reddy SV
J Cell Physiol; 2018 Aug; 233(8):6125-6134. PubMed ID: 29323724
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma.
Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J
Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
8. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption.
Hwang YS; Lee SK; Park KK; Chung WY
Oral Oncol; 2012 Jan; 48(1):40-8. PubMed ID: 21925926
[TBL] [Abstract][Full Text] [Related]
9. Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Martin CK; Dirksen WP; Carlton MM; Lanigan LG; Pillai SP; Werbeck JL; Simmons JK; Hildreth BE; London CA; Toribio RE; Rosol TJ
Vet Comp Oncol; 2015 Sep; 13(3):203-17. PubMed ID: 23651067
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL.
Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A
J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422
[TBL] [Abstract][Full Text] [Related]
11. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid-related protein plays a critical role in bone invasion by oral squamous cell carcinoma.
Takayama Y; Mori T; Nomura T; Shibahara T; Sakamoto M
Int J Oncol; 2010 Jun; 36(6):1387-94. PubMed ID: 20428761
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats.
Wypij JM; Fan TM; Fredrickson RL; Barger AM; de Lorimier LP; Charney SC
J Vet Intern Med; 2008; 22(1):158-63. PubMed ID: 18289304
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma.
Lv Z; Wu X; Cao W; Shen Z; Wang L; Xie F; Zhang J; Ji T; Yan M; Chen W
J Exp Clin Cancer Res; 2014 Dec; 33(1):100. PubMed ID: 25539663
[TBL] [Abstract][Full Text] [Related]
15. Characterization of different osteoclast phenotypes in the progression of bone invasion by oral squamous cell carcinoma.
Quan J; Hou Y; Long W; Ye S; Wang Z
Oncol Rep; 2018 Mar; 39(3):1043-1051. PubMed ID: 29286135
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo.
Furuta H; Osawa K; Shin M; Ishikawa A; Matsuo K; Khan M; Aoki K; Ohya K; Okamoto M; Tominaga K; Takahashi T; Nakanishi O; Jimi E
Int J Cancer; 2012 Sep; 131(5):E625-35. PubMed ID: 22262470
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts promote bone invasion in oral squamous cell carcinoma.
Elmusrati AA; Pilborough AE; Khurram SA; Lambert DW
Br J Cancer; 2017 Sep; 117(6):867-875. PubMed ID: 28742795
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.
Zhao H; Cai W; Li S; Da Z; Sun H; Ma L; Lin Y; Zhi D
Childs Nerv Syst; 2013 Jul; 29(7):1097-105. PubMed ID: 23559392
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment.
Sambandam Y; Sundaram K; Liu A; Kirkwood KL; Ries WL; Reddy SV
Oncogene; 2013 Jan; 32(1):97-105. PubMed ID: 22330139
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Martin CK; Werbeck JL; Thudi NK; Lanigan LG; Wolfe TD; Toribio RE; Rosol TJ
Cancer Res; 2010 Nov; 70(21):8607-16. PubMed ID: 20959474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
